...Banque. The firm declined to comment. Last May, EdRIP backed idiopathic pulmonary fibrosis (IPF) company Genoa Pharmaceuticals Inc....

...By installing a proven CEO and ponying up sufficient cash to clear Phase II development, Genoa Pharmaceuticals Inc....

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) raised $62 million in a series A round on May 15...
...Investment Partners . Also participating were Novo A/S , RiverVest Venture Partners and TPG Biotech. Genoa Pharmaceuticals Inc....

...Pulmonary play Genoa Pharmaceuticals Inc. (Seattle, Wash.) said it raised $62 million in a series A financing led...

...BioCentury, July 14). Pirfenidone is a small molecule inhibitor of proinflammatory cytokines and pro-fibrotic cytokines. Genoa Pharmaceuticals Inc....

...rights in South Korea and Taiwan and markets it as Pirespa for IPF in Japan. Genoa Pharmaceuticals Inc....

...University , ultimately wanted to see studies of pirfenidone plus fasudil. Kolb is collaborating with Genoa Pharmaceuticals Inc....
...Kasei Pharma Corp. , Tokyo, Japan Firestone Institute for Respiratory Health , Hamilton, Ontario, Canada Genoa Pharmaceuticals Inc....